Literature DB >> 33140116

Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.

Ismet Hortu1,2, Elif Karadadas3, Gokay Ozceltik4, Erol Tavmergen4,5, Ege Nazan Tavmergen Goker4,5, Gurkan Yigitturk6, Oytun Erbas7.   

Abstract

PURPOSE: Ovarian hyperstimulation syndrome (OHSS) is a life-threatening complication of ovarian stimulation in reproductive medicine. Here, we aimed to investigate the role of oxytocin (OT) and cabergoline in the prevention and alleviation of the OHSS in an animal model.
METHODS: Thirty-five female immature Wistar rats were randomly assigned to five groups. The control group (n = 7) received saline only for five consecutive days. Remaining twenty-eight rats received 10 IU of pregnant mare serum gonadotropin (PMSG) followed by 30 IU of human chorionic gonadotropin (hCG) to induce OHSS. Group 2 (n = 7) was managed with no additional intervention after the induction of OHSS. Group 3 (n = 7) received 100 μg/kg cabergoline 2 h before the PMSG injection for four consecutive days and 2 h before the hCG injection on the fifth day. Group 4 (n = 7) and group 5 (n = 7) received 80 μg/kg and 160 μg/kg OT after induction of OHSS, respectively. Oxytocin was administered 2 h before the PMSG injection for four consecutive days and 2 h before the hCG injection on the fifth day. Body and ovary weight, vascular permeability (VP), VEGF expression in the ovaries, and levels of VEGF in the peritoneal fluids were examined in all animals.
RESULTS: Cabergoline and OT reduced body weight, ovary weight, and VP compared to that of the OHSS group (p < 0.05). VEGF expressions in ovaries and peritoneal VEGF levels were decreased in cabergoline and OT groups compared to that of the OHSS groups (p < 0.001 for cabergoline and OT-80 μg/kg; p < 0.00001 for OT-160 μg/kg). However, there was no statistically significant difference in these parameters between the OT and cabergoline groups.
CONCLUSION: Both OT and cabergoline were active in the alleviation of OHSS through suppression of VEGF and VP. Overall, we conclude that OT is effective for downregulation for VEGF and improvement in vascular permeability in OHSS.

Entities:  

Keywords:  Animal model; Cabergoline; Ovarian hyperstimulation syndrome; Oxytocin; VEGF

Mesh:

Substances:

Year:  2020        PMID: 33140116     DOI: 10.1007/s00404-020-05855-1

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  3 in total

Review 1.  New insights in mechanisms for development of ovarian hyperstimulation syndrome.

Authors:  Miro Kasum
Journal:  Coll Antropol       Date:  2010-09

Review 2.  Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.

Authors:  Arianna D'Angelo; Nazar N Amso; Rudaina Hassan
Journal:  Cochrane Database Syst Rev       Date:  2017-05-23

Review 3.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma Mourad; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30
  3 in total
  2 in total

1.  Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model.

Authors:  Shutian Jiang; Wenzhi Li; Xinxi Zhao; Li Chen; Yanping Kuang
Journal:  Drug Des Devel Ther       Date:  2022-02-18       Impact factor: 4.162

2.  Coenzyme Q10 improves ovarian histology and attenuates the expression of angiogenesis-associated proteins in the ovary of rats with experimental hyperstimulation syndrome.

Authors:  Zahra Darabi; Zahra Basir; Mohammad Reza Tabandeh; Zohreh Ghotbeddin
Journal:  Iran J Basic Med Sci       Date:  2022-08       Impact factor: 2.532

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.